Transaction · 0001434647-26-000075

McFarlane Neil F.

McFarlane Neil F., PRES, reported an open-market or private sale at ZEVRA THERAPEUTICS, INC. involving 20000.000000 shares for an estimated $224948.00. Reported holdings after the transaction were 417225.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES
ZVRAZEVRA THERAPEUTICS, INC.
Trade date
Oct 12, 2026
Filing date
Oct 13, 2026
View on SEC Insider profile
Estimated value-$224kShares × reported price
Shares traded20.0k$11.25 per share
Holdings after417kDirect
% of reported position traded4.57%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 437,225 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ZVRA price since this filing

Daily closing prices, with the filing date and available return windows
ZVRA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.1%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001434647-26-000075
Common Stock
Transaction date
Oct 12, 2026
Filed Oct 13, 2026, 08:24 PM · 1d delay
Shares
20,000 sh
$11.25 per share
Estimated value
-$224k
Computed from shares × price
Holdings after
417,225 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

  2. F2

    Adoption date of referenced 10b5-1(c) plan is: 03-25-2026

  3. F3

    This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon r…

  4. F4

    25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting da…

Original filing · 0001434647-26-000075
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ZVRA